This finding suggested that anti-PD-L1 treatment increased the expression of bFGF in LNCaP cells that do not express bFGF, suggesting that this increase in bFGF expression may be one of the mechanisms of immunotherapy resistance in prostate cancer cells with high PD-L1 expression. The gene discussed is FGF2; the disease is prostate carcinoma.